KEYTRUDA® (pembrolizumab 100mg)
| Product Overview | |
| Generic Name | KEYTRUDA® (pembrolizumab 100mg) |
| Brand Name(s) | KEYTRUDA |
| Form | Intravenous solution, vial (concentrate for infusion) |
| Strength | 100 mg/4 mL (25 mg/mL) |
| Therapeutic Class | PD‑1 immune checkpoint inhibitor |
| ATC Code | L01FF02 |
| Manufacturing & Regulatory | |
| Manufacturer | Merck |
| Country | USA, EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Not publicly disclosed |
| COFEPRIS | Clave : 010.000.6153.00 |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Not publicly available as parallel traded molecule |
Description
Keytruda is a PD-1 immune checkpoint inhibitors indicated across a range of advanced cancers, including metastatic melanoma, NSCLC, head and neck squamous cell carcinoma, urothelial carcinoma, MSI‑H/dMMR tumors, Hodgkin lymphoma, cervical cancer, gastric/gastroesophageal cancers, hepatocellular carcinoma, triple-negative breast cancer, endometrial carcinoma, biliary tract cancer, and locally advanced head & neck SCC (neoadjuvant/adjuvant
